The DOI matches its Crossref record; 448 of the 448 references it cites were found in a registry or an index.
Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., & Freeman, B. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1620 · Cited by 7,029
Johnston, L. D., O'Malley, P. M., Bachman, J. G., & Schulenberg, J. E. (2009) · PsycEXTRA Dataset · doi:10.1037/e560352009-001 · Cited by 6,921
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788 · cited 1×
“A G1947A substitution in the COMT gene that results in the valine108methyonine substitution in the soluble COMT and in the valine158methyonine substitution in the membrane-bound COMT produces an enzyme with low catalytic activity [107–109].”
BackgroundPharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
(2017) · Institute for Social Research eBooks · doi:10.3998/2027.42/139710 · Cited by 1,364
Pemble, S., Schroeder, K. R., Spencer, S. R., Meyer, D. J., Hallier, E., Bolt, H. M., Ketterer, B., & Taylor, J. B. (1994) · Biochemical Journal · doi:10.1042/bj3000271 · Cited by 1,296
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Lotta, T., Vidgren, J., Tilgmann, C., Ulmanen, I., Melen, K., Julkunen, I., & Taskinen, J. (1995) · Biochemistry · doi:10.1021/bi00013a008 · Cited by 1,167
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1997) · Europe PMC (PubMed Central) · Cited by 973
Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2001) · Synapse · doi:10.1002/1098-2396(20010101)39:1<32::aid-syn5>3.0.co;2-3 · Cited by 938
Mattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., & Weinberger, D. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931309100 · Cited by 893 · cited 2×
“The results of this study, where the effects of D-amphetamine were monitored with brain imaging techniques, showed that the individuals homozygous for the mutation (genotype met/met) were more prone to the neurotoxic effects of the drug [115].”
ResultCytochromes P450 and metabolism of xenobiotics
Anzenbacher, P., & Anzenbacherová, E. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000897 · Cited by 889
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Seidegård, J., Vorachek, W. R., Pero, R. W., & Pearson, W. R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7293 · Cited by 727
Ali-Osman, F., Akande, O., Antoun, G., Mao, J.-X., & Buolamwini, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.15.10004 · Cited by 713
Sulzer, D., Chen, T., Lau, Y., Kristensen, H., Rayport, S., & Ewing, A. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-04102.1995 · Cited by 688
Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686
Ingelman-Sundberg, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.007 · Cited by 676
The Role of Serotonin in Antipsychotic Drug Action
Meltzer, H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00046-9 · Cited by 662
McCann, U., Szabo, Z., Scheffel, U., Dannals, R., & Ricaurte, G. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04329-3 · Cited by 660
Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
Monaghan, G., Ryan, M., Hume, R., Burchell, B., & Seddon, R. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91273-8 · Cited by 585
Weinshilboum, R. M., Otterness, D. M., & Szumlanski, C. L. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.19 · Cited by 549
O'Hearn, E., Battaglia, G., De Souza, E., Kuhar, M., & Molliver, M. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02788.1988 · Cited by 542
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
Ingelman-Sundberg, M., Oscarson, M., & McLellan, R. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01363-2 · Cited by 539
Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.
Schmidt, C. J. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22673-8 · Cited by 529
Monoamine transporters and psychostimulant drugs
Rothman, R. B., & Baumann, M. H. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.054 · Cited by 502
Azmitia, E. C. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00614-1 · Cited by 497
Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury
Yi, J.-H., & Hazell, A. S. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.001 · Cited by 479
Battaglia, G., Yeh, S. Y., O'Hearn, E., Molliver, M. E., Kuhar, M. J., & De Souza, E. B. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39191-3 · Cited by 458
Commins, D. L., Vosmer, G., Virus, R. M., Woolverton, W. L., Schuster, C. R., & Seiden, L. S. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-5347(25)00317-9 · Cited by 453
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448
Johansson, I., Oscarson, M., Yue, Q. Y., Bertilsson, L., Sjöqvist, F., & Ingelman-Sundberg, M. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09721-4 · Cited by 430
Han, D. D., & Gu, H. H. (2006) · BMC Pharmacology · doi:10.1186/1471-2210-6-6 · Cited by 419
Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse.
O'Callaghan, J. P., & Miller, D. B. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22433-8 · Cited by 409
Non‐linear pharmacokinetics of MDMA (‘ecstasy’) in humans
De La Torre, R., Farré, M., Ortuño, J., Mas, M., Brenneisen, R., Roset, P. N., Segura, J., & Camí, J. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00121.x · Cited by 401
Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F., & Ingelman-Sundberg, M. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20152-5 · Cited by 392
Ramamoorthy, S., & Blakely, R. D. (1999) · Science · doi:10.1126/science.285.5428.763 · Cited by 392
Globus, M. Y. ‐., Busto, R., Lin, B., Schnippering, H., & Ginsberg, M. D. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65031250.x · Cited by 383
Spencer, J. P. E., Jenner, P., Daniel, S. E., Lees, A. J., Marsden, D. C., & Halliwell, B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052112.x · Cited by 373
Memory impairment in abstinent MDMA ("Ecstasy") users
Bolla, K. I., McCann, U. D., & Ricaurte, G. A. (1998) · Neurology · doi:10.1212/wnl.51.6.1532 · Cited by 373
Hemeryck, A., & Belpaire, F. (2002) · Current Drug Metabolism · doi:10.2174/1389200023338017 · Cited by 368
Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals
Ricaurte, G., Bryan, G., Strauss, L., Seiden, L., & Schuster, C. (1985) · Science · doi:10.1126/science.4023719 · Cited by 367
Nash, J. F., & Yamamoto, B. K. (1992) · Brain Research · doi:10.1016/0006-8993(92)90713-j · Cited by 354
Stone, D. M., Stahl, D. C., Hanson, G. R., & Gibb, J. W. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90555-8 · Cited by 346
Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex
Willins, D. L., Deutch, A. Y., & Roth, B. L. (1997) · Synapse · doi:10.1002/(sici)1098-2396(199709)27:1<79::aid-syn8>3.0.co;2-a · Cited by 345
Malberg, J. E., & Seiden, L. S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-13-05086.1998 · Cited by 344
Hatzidimitriou, G., McCann, U. D., & Ricaurte, G. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05096.1999 · Cited by 339
McCann, U. D., Ridenour, A., Shaham, Y., & Ricaurte, G. A. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.15 · Cited by 332
Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2
del Amo, E. M., Urtti, A., & Yliperttula, M. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.06.015 · Cited by 319
Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology
Ballatori, N., Krance, S. M., Marchan, R., & Hammond, C. L. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.004 · Cited by 318
Phosphorylation and Regulation of Antidepressant-sensitive Serotonin Transporters
Ramamoorthy, S., Giovanetti, E., Qian, Y., & Blakely, R. D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.2458 · Cited by 315
MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons
Battaglia, G., Yeh, S. Y., & De Souza, E. B. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90155-4 · Cited by 312
Johnson, M. P., Hoffman, A. J., & Nichols, D. E. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90615-1 · Cited by 306
Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene
Johne, A., Köpke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., Hoffmeyer, S., Kerb, R., Fromm, M. F., Brinkmann, U., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129196 · Cited by 306
Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites
Battaglia, G., Brooks, B. P., Kulsakdinun, C., & De Souza, E. B. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90056-8 · Cited by 301
Ricaurte, G. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410010059035 · Cited by 300
McCann, U. D., Mertl, M., Eligulashvili, V., & Ricaurte, G. A. (1999) · Psychopharmacology · doi:10.1007/s002130050967 · Cited by 300
Schmidt, C. J., Levin, J. A., & Lovenberg, W. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90729-5 · Cited by 297
Hall, A. P., & Henry, J. A. (2006) · British Journal of Anaesthesia · doi:10.1093/bja/ael078 · Cited by 294
Steketee, J. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00233-3 · Cited by 293
(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals
Ricaurte, G. A., Yuan, J., & McCann, U. D. (2000) · Neuropsychobiology · doi:10.1159/000026664 · Cited by 292
Brain Temperature Alters Hydroxyl Radical Production during Cerebral Ischemia/Reperfusion in Rats
Kil, H. Y., Zhang, J., & Piantadosi, C. A. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199601000-00012 · Cited by 291
Vanderschuren, L. J. M. J., Schmidt, E. D., De Vries, T. J., Van Moorsel, C. A. P., Tilders, F. J. H., & Schoffelmeer, A. N. M. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-21-09579.1999 · Cited by 290
Semple, D. M., Ebmeier, K. P., Glabus, M. F., O'Carroll, R. E., & Johnstone, E. C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.1.63 · Cited by 280
Marchitti, S. A., Deitrich, R. A., & Vasiliou, V. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.1 · Cited by 280
Pathology of deaths associated with "ecstasy" and "eve" misuse.
Milroy, C. M., Clark, J. C., & Forrest, A. R. (1996) · Journal of Clinical Pathology · doi:10.1136/jcp.49.2.149 · Cited by 270
Fischer, C., Hatzidimitriou, G., Wlos, J., Katz, J., & Ricaurte, G. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-08-05476.1995 · Cited by 268
Ricaurte, G. A., Martello, A. L., Katz, J. L., & Martello, M. B. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11083-5 · Cited by 268
Baumann, M. H., Wang, X., & Rothman, R. B. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0322-6 · Cited by 265
Biochemical and toxicological properties of the oxidation products of catecholamines
Bindoli, A., Rigobello, M. P., & Deeble, D. J. (1992) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(92)90182-g · Cited by 264
Miller, D. B., & O'Callaghan, J. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22434-x · Cited by 259
Neurotoxicity of MDMA and Related Compounds: Anatomic Studiesa
MOLLIVER, M. E., BERGER, U. V., MAMOUNAS, L. A., MOLLIVER, D. C., O'HEARN, E., & WILSON, M. A. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16916.x · Cited by 252
Gudelsky, G. A., & Nash, J. F. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66010243.x · Cited by 251
Zhu, B. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337586 · Cited by 251
Reneman, L., Booij, J., de Bruin, K., Reitsma, J. B., de Wolff, F. A., Gunning, W. B., den Heeten, G. J., & van den Brink, W. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06888-x · Cited by 251
LIMA, J., THOMASON, D., MOHAMED, M., EBERLE, L., SELF, T., & JOHNSON, J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70071-8 · Cited by 250
Baumann, M. H., Clark, R. D., Budzynski, A. G., Partilla, J. S., Blough, B. E., & Rothman, R. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300585 · Cited by 248
Liechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00126-3 · Cited by 245 · cited 1×
“The hallucinogenic effects of MDMA are reported to be decreased by pretreatment with ketanserin (a 5-HT2A antagonist) [214] and also by selective 5-HTT inhibitors like citalopram, paroxetine, and fluoxetine [216, 217].”
BackgroundRicaurte, G. A., DeLanney, L. E., Irwin, I., & Langston, J. W. (1988) · Brain Research · doi:10.1016/0006-8993(88)91309-1 · Cited by 245
O'Shea, E., Granados, R., Esteban, B., Colado, M. I., & Green, A. R. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00029-x · Cited by 242
Amphetamine induces dopamine efflux through a dopamine transporter channel
Kahlig, K. M., Binda, F., Khoshbouei, H., Blakely, R. D., McMahon, D. G., Javitch, J. A., & Galli, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407737102 · Cited by 239
Tucker, G. T., Lennard, M. S., Ellis, S. W., Woods, H. F., Cho, A. K., Lin, L. Y., Hiratsuka, A., Schmitz, D. A., & Chu, T. Y. Y. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90386-7 · Cited by 236
Parrott, A. C. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1712-7 · Cited by 232
Morgan, M., McFie, L., Fleetwood, L., & Robinson, J. (2002) · Psychopharmacology · doi:10.1007/s002130100907 · Cited by 227
Mechan, A. O., Esteban, B., O'Shea, E., Elliott, J. M., Colado, M. I., & Green, A. R. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704442 · Cited by 221
Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat
Gordon, C. J., Watkinson, W. P., O'Callaghan, J. P., & Miller, D. B. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90288-d · Cited by 220
Cognitive performance amongst recreational users of "ecstasy"
Rodgers, J. (2000) · Psychopharmacology · doi:10.1007/s002130000467 · Cited by 218
The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat
Yamamoto, B. K., & Spanos, L. J. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90564-x · Cited by 217
Pharmacogenetics of Sulfotransferase
Nagata, K., & Yamazoe, Y. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.159 · Cited by 215
Berger, U. V., Gu, X. F., & Azmitia, E. C. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90023-w · Cited by 210
Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance
Miners, J. O., McKinnon, R. A., & Mackenzie, P. I. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00449-3 · Cited by 210
Reneman, L., Booij, J., Schmand, B., van den Brink, W., & Gunning, B. (2000) · Psychopharmacology · doi:10.1007/s002130050057 · Cited by 210
Ecstasy and the dance of death.
Henry, J. A. (1992) · BMJ · doi:10.1136/bmj.305.6844.5 · Cited by 209
Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs (‘Ecstasy’)
Maurer, H. H., Bickeboeller-Friedrich, J., Kraemer, T., & Peters, F. T. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00207-6 · Cited by 206
McCann, U. D., Szabo, Z., Seckin, E., Rosenblatt, P., Mathews, W. B., Ravert, H. T., Dannals, R. F., & Ricaurte, G. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300736 · Cited by 204
Methylenedioxymethamphetamine: A potentially neurotoxic amphetamine analogue
Schmidt, C. J., Wu, L., & Lovenberg, W. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90140-8 · Cited by 202
Spanos, L. J., & Yamamoto, B. K. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90044-0 · Cited by 200
The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*
Freudenmann, R. W., Öxler, F., & Bernschneider‐Reif, S. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01511.x · Cited by 199
Hiramatsu, M., Kumagai, Y., Unger, S. E., & Cho, A. K. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12653-0 · Cited by 198
Kreth, K.-P., Kovar, K.-A., Schwab, M., & Zanger, U. M. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00284-7 · Cited by 198
Gerra, G., Zaimovic, A., Franchini, D., Palladino, M., Giucastro, G., Reali, N., Maestri, D., Caccavari, R., Delsignore, R., & Brambilla, F. (1998) · International Journal of Psychophysiology · doi:10.1016/s0167-8760(97)00071-8 · Cited by 196
PANNU, R., & SINGH, I. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.04.010 · Cited by 195
Cellular localization of serotonin2A (5HT2A) receptors in the rat brain
Xu, T., & Pandey, S. C. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(99)00278-6 · Cited by 194
Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines
Thomas, D. M., Dowgiert, J., Geddes, T. J., Francescutti-Verbeem, D., Liu, X., & Kuhn, D. M. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.06.065 · Cited by 193
Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome
Aono, S., Keino, H., Yamada, Y., Adachi, Y., Nanno, T., Uyama, E., Koiwai, O., & Sato, H. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90702-5 · Cited by 192
Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans
de la Torre, R., & Farré, M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.08.001 · Cited by 192
Altered states: the clinical effects of Ecstasy
Cole, J. C., & Sumnall, H. R. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00003-2 · Cited by 192
Pharmacogenetics of the major polymorphic metabolizing enzymes
Daly, A. K. (2003) · Fundamental & Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00119.x · Cited by 189
Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.-U., Schwab, M., & Zanger, U. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200010000-00001 · Cited by 189
Schmidt, C. J., & Taylor, V. L. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90566-1 · Cited by 187
Can Drugs Be Used to Enhance the Psychotherapeutic Process?
Grinspoon, L., & Bakalar, J. B. (1986) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1986.40.3.393 · Cited by 187
Pharmacogenetics of the serotonin transporter
Lesch, K. P., & Gutknecht, L. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.012 · Cited by 186
Stone, D. M., Johnson, M., Hanson, G. R., & Gibb, J. W. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20051-9 · Cited by 184
Esteban, B., O'Shea, E., Camarero, J., Sanchez, V., Green, A. R., & Colado, M. I. (2001) · Psychopharmacology · doi:10.1007/s002130000645 · Cited by 183
Fox, H., McLean, A., Turner, J., Parrott, A., Rogers, R., & Sahakian, B. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1071-9 · Cited by 181
Nash, J. F., Meltzer, H. Y., & Gudelsky, G. A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24086-1 · Cited by 179
Sprague, J. E., Everman, S. L., & Nichols, D. E. (1998) · PubMed · Cited by 178
Amphetamines induce apoptosis and regulation of bcl‐x splice variants in neocortical neurons
Stumm, G., Schlegel, J., Schäfer, T., Würz, C., Mennel, H. D., Krieg, J. ‐., & Vedder, H. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.9.1065 · Cited by 177
Colado, M. I., O'Shea, E., Granados, R., Misra, A., Murray, T. K., & Green, A. R. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701201 · Cited by 175
Crespi, D., Mennini, T., & Gobbi, M. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701325 · Cited by 174
Colado, M. I., O'Shea, E., Granados, R., Murray, T. K., & Green, A. R. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701213 · Cited by 174
Interactions of amphetamine analogs with human liver CYP2D6
Wu, D., Otton, S. V., Inaba, T., Kalow, W., & Sellers, E. M. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00014-2 · Cited by 173
Low-dose MDMA (“ecstasy”) induces vasopressin secretion
Henry, J. A., Fallon, J. K., Kicman, A. T., Hutt, A. J., Cowan, D. A., & Forsling, M. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78744-4 · Cited by 171
Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics
Farré, M., de la Torre, R., Ó Mathúna, B., Roset, P. N., Peiró, A. M., Torrens, M., Ortuño, J., Pujadas, M., & Camí, J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1789-7 · Cited by 169
Reneman, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00366-9 · Cited by 169
Colado, M. I., Williams, J. L., & Green, A. R. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15037.x · Cited by 165
Postlipopolysaccharide Oxidative Damage of Mitochondrial DNA
Suliman, H. B., Carraway, M. S., & Piantadosi, C. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-518oc · Cited by 165
Insel, T. R., Battaglia, G., Johannessen, J. N., Marra, S., & De Souza, E. B. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23487-5 · Cited by 162
CHARACTERIZATION OF THREE NEW PSYCHOTOMIMETICS
Alexander, T., & Nichols, D. E. (1978) · The Psychopharmacology of Hallucinogens · doi:10.1016/b978-0-08-021938-7.50010-2 · Cited by 162
Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter
Partilla, J. S., Dempsey, A. G., Nagpal, A., Blough, B. E., Baumann, M. H., & Rothman, R. B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103622 · Cited by 161
Leonardi, E. T. K., & Azmitia, E. C. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.26 · Cited by 161
Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome
De Morais, S. M. F., Uetrecht, J. P., & Wells, P. G. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90106-9 · Cited by 160
Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity
Pubill, D., Canudas, A. M., Pallàs, M., Camins, A., Camarasa, J., & Escubedo, E. (2003) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0747-y · Cited by 160
N-Acetyl cysteine protects against injury in a rat model of focal cerebral ischemia
Sekhon, B., Sekhon, C., Khan, M., Patel, S. J., Singh, I., & Singh, A. K. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02244-3 · Cited by 159
MDMA Elicits Behavioral and Neurochemical Sensitization in Rats
Kalivas, P. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00195-4 · Cited by 158
Thomasius, R., Zapletalova, P., Petersen, K., Buchert, R., Andresen, B., Wartberg, L., Nebeling, B., & Schmoldt, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106059486 · Cited by 158
de la Torre, R., Farr, M., Navarro, M., Pacifici, R., Zuccaro, P., & Pichini, S. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443030-00002 · Cited by 156
Tobacco Carcinogen-Detoxifying Enzyme UGT1A7 and Its Association With Orolaryngeal Cancer Risk
Zheng, Z., Park, J. Y., Guillemette, C., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.18.1411 · Cited by 156
Progress in Monoamine Oxidase (MAO) Research in Relation to Genetic Engineering
Nagatsu, T. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(03)00085-8 · Cited by 154
Tancer, M., & Johanson, C.-E. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00172-8 · Cited by 153
Impulsivity, risk taking and recreational ‘ecstasy’ (MDMA) use
Butler, G., & Montgomery, A. M. J. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.04.003 · Cited by 153
Itzhak, Y., Gandia, C. E., Huang, P. L., & Ali, S. F. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37339-2 · Cited by 153
Broening, H. W., Bowyer, J. F., & Slikker, W. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12053-3 · Cited by 151
Uncoupling the agony from ecstasy
Mills, E., Banks, M. L., Sprague, J. E., & Finkel, T. (2003) · Nature · doi:10.1038/426403a · Cited by 151
Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
Freedman, R. R., Johanson, C., & Tancer, M. E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0149-6 · Cited by 150
Chu, T., Kumagai, Y., Distefano, E. W., & Cho, A. K. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02397-6 · Cited by 150
Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users
Gouzoulis‐Mayfrank, E., Thimm, B., Rezk, M., Hensen, G., & Daumann, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00114-3 · Cited by 148
Malberg, J. E., Sabol, K. E., & Seiden, L. S. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20131-8 · Cited by 147
McCann, U. D., Szabó, Z. R., Vranešić, M., Palermo, M., Mathews, W. B., Ravert, H. T., Dannals, R. F., & Ricaurte, G. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1218-4 · Cited by 146
Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ???Ecstasy???)
McCann, U. D., Slate, S. O., & Ricaurte, G. A. (1996) · Drug Safety · doi:10.2165/00002018-199615020-00003 · Cited by 145
Morgan, M. J., Impallomeni, L. C., Pirona, A., & Rogers, R. D. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300953 · Cited by 144
Liechti, M. E., & Vollenweider, F. X. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400313 · Cited by 144
Broening, H. W., Morford, L. L., Inman-Wood, S. L., Fukumura, M., & Vorhees, C. V. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03228.2001 · Cited by 143
Yamamoto, B. K., Nash, J. F., & Gudelsky, G. A. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09555-2 · Cited by 142
Owen, R., Sangkuhl, K., Klein, T. E., & Altman, R. B. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832e0e97 · Cited by 141
Fallon, J. K., Kicman, A. T., Henry, J. A., Milligan, P. J., Cowan, D., & Hutt, A. J. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.7.1058 · Cited by 139
Schenk, S., Gittings, D., Johnstone, M., & Daniela, E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1407-0 · Cited by 137
Cervinski, M., Foster, J., & Vaughan, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501969200 · Cited by 136
Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats.
Scanzello, C. R., Hatzidimitriou, G., Martello, A. L., Katz, J. L., & Ricaurte, G. A. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10168-7 · Cited by 135
Ecstasy (MDMA) in Recreational Users: Self-Reported Psychological and Physiological Effects
DAVISON, D., & Parrott, A. C. (1997) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199705/06)12:3<221::aid-hup854>3.0.co;2-c · Cited by 134
Sadzot, B., Baraban, J. M., Glennon, R. A., Lyon, R. A., Leonhardt, S., Jan, C.-R., & Titeler, M. (1989) · Psychopharmacology · doi:10.1007/bf00441948 · Cited by 132
Colado, M. I., Murray, T. K., & Green, A. R. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb12846.x · Cited by 132
MDMA (“Ecstasy”) Abuse and High-Risk Sexual Behaviors Among 169 Gay and Bisexual Men
Klitzman, R., Pope, H. G., & Hudson, J. I. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1162 · Cited by 132
Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study
Cowan, R. L., Lyoo, I. K., Sung, S. M., Ahn, K. H., Kim, M. J., Hwang, J., Haga, E., Vimal, R. L. P., Lukas, S. E., & Renshaw, P. F. (2003) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.07.001 · Cited by 132
How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?
Kish, S. J. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00708-0 · Cited by 132
Fantegrossi, W. E., Ullrich, T., Rice, K. C., Woods, J. H., & Winger, G. D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1021-6 · Cited by 132
STONE, D., Gr, H., & Gibb, J. W. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90017-7 · Cited by 131
Cloning, expression and structure of catechol-O-methyltransferase
Lundstrom, K. H., Tenhunen, J., Tilgmann, C., Karhunen, T., Panula, P., & Ulmanen, I. (1995) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(95)00071-2 · Cited by 131
Roiser, J. P., Rogers, R. D., Cook, L. J., & Sahakian, B. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0495-z · Cited by 130
Ecstasy: Are animal data consistent between species and can they translate to humans?
Easton, N., & Marsden, C. A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106061153 · Cited by 127
Deamination of 5‐Hydroxytryptamine by Both Forms of Monoamine Oxidase in the Rat Brain
Fowler, C. J., & Tipton, K. F. (1982) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1982.tb08692.x · Cited by 126
Serotonergic Neurotoxic Metabolites of Ecstasy Identified in Rat Brain
Jones, D. C., Duvauchelle, C. L., Ikegami, A., Olsen, C. M., Lau, S. S., de la Torre, R., & Monks, T. J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.077628 · Cited by 126
Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET.
Buchert, R., Thomasius, R., Nebeling, B., Petersen, K. U., Obrocki, J., Jenicke, L., Wilke, F., Wartberg, L., Zapletalova, P., & Clausen, M. (2003) · PubMed · Cited by 126
Ecstasy: pharmacology and neurotoxicity
Morton, J. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.007 · Cited by 125
Verheyden, S. L., Hadfield, J., Calin, T., & Curran, V. H. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0995-9 · Cited by 123
Jayanthi, L. D., Samuvel, D. J., Blakely, R. D., & Ramamoorthy, S. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.009555 · Cited by 123
Colado, M. I., Camarero, J., Mechan, A. O., Sánchez, V., Esteban, B. M., Elliott, J. M., & Green, A. R. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704435 · Cited by 122
Monks, T. J., Jones, D. C., Bai, F., & Lau, S. S. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00008 · Cited by 122
Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user
Kish, S. J., Furukawa, Y., Ang, L.-C., Vorce, S. P., & Kalasinsky, K. S. (2000) · Neurology · doi:10.1212/wnl.55.2.294 · Cited by 119
Fantegrossi, W. E., Godlewski, T., Karabenick, R. L., Stephens, J. M., Ullrich, T., Rice, K. C., & Woods, J. H. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1261-5 · Cited by 118
Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): a stressor on the immune system
Connor, T. J. (2004) · Immunology · doi:10.1111/j.0019-2805.2004.01847.x · Cited by 117
Farré, M., Abanades, S., Roset, P. N., Peiró, A. M., Torrens, M., O'Mathúna, B., Segura, M., & de la Torre, R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129056 · Cited by 117
Hussain, S. M., Slikker, W., & Ali, S. F. (1996) · Neurochemistry International · doi:10.1016/0197-0186(95)00114-x · Cited by 116
Jacobsen, L. K., Mencl, W. E., Pugh, K. R., Skudlarski, P., & Krystal, J. H. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1679-4 · Cited by 116
Sprague, J. E., & Nichols, D. E. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09490-x · Cited by 115
‘Ecstasy’ Psychosis and Flashbacks
Creighton, F. J., Black, D. L., & Hyde, C. E. (1991) · The British Journal of Psychiatry · doi:10.1192/bjp.159.5.713 · Cited by 115
Tancer, M., & Johanson, C.-E. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0576-z · Cited by 113
Quednow, B., Jessen, F., Kühn, K., Maier, W., Daum, I., & Wagner, M. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106061200 · Cited by 112
Spencer, J. P. E., Whiteman, M., Jenner, P. G., & Halliwell, B. B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00808.x · Cited by 111
Miyazaki, I., Asanuma, M., Diaz-Corrales, F. J. J., Fukuda, M., Kitaichi, K., Miyoshi, K., & Ogawa, N. (2006) · The FASEB Journal · doi:10.1096/fj.05-4996fje · Cited by 111
Fone, K. C. F., Beckett, S. R. G., TOPHAM, I. A., Swettenham, J. B., Ball, M., & Maddocks, L. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0931-z · Cited by 111
Fantegrossi, W. E., Woolverton, W. L., Kilbourn, M. R., Sherman, P. S., Yuan, J., Hatzidimitriou, G., Ricaurte, G. A., Woods, J. H., & Winger, G. D. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300442 · Cited by 111
An Exploration of the History and Controversies Surrounding MDMA and MDA
Pentney, A. R. (2001) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2001.10400568 · Cited by 110
Slikker, W., Ali, S. F., Scallet, A. C., Frith, C. H., Newport, G. D., & Bailey, J. (1988) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(88)90285-2 · Cited by 110
Farfel, G. M., & Seiden, L. S. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24411-1 · Cited by 110
Bai, F., Lau, S. S., & Monks, T. J. (1999) · Chemical Research in Toxicology · doi:10.1021/tx990084t · Cited by 109
Farfel, G. M., & Seiden, L. S. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24505-0 · Cited by 108
Wolff, K., Tsapakis, E. M., Winstock, A. R., Hartley, D., Holt, D., Forsling, M. L., & Aitchison, K. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106061514 · Cited by 108
Shankaran, M., & Gudelsky, G. A. (1999) · Psychopharmacology · doi:10.1007/s002130051143 · Cited by 108
Cited by
Parkinson’s disease: animal models and dopaminergic cell vulnerability
Blesa, J., & Przedborski, S. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00155 · Cited by 480
Toxicity of amphetamines: an update
Carvalho, M., Carmo, H., Costa, V. M., Capela, J. P., Pontes, H., Remião, F., Carvalho, F., & Bastos, M. D. L. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0815-5 · Cited by 431
Self-citationMechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Schenk, S., & Highgate, Q. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15348 · Cited by 48
50-kHz calls in rats: Effects of MDMA and the 5-HT1A receptor agonist 8-OH-DPAT
Sadananda, M., Natusch, C., Karrenbauer, B., & Schwarting, R. K. W. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.01.012 · Cited by 43
Metadata
- Authors
- Capela, J. P., Carmo, H., Remião, F., Bastos, M. L., Meisel, A., & Carvalho, F.
- Venue
- Molecular Neurobiology
- Published
- 2009-04-17
- Volume
- 39
- Issue
- 3
- Pages
- 210-271
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2048841731
- Cited by
- 290
- References
- 448
- FWCI
- 32.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.